Technical Analysis for LQDA - Liquidia Technologies, Inc.

Grade Last Price % Change Price Change
grade F 3.45 -4.43% -0.16
LQDA closed down 4.43 percent on Monday, November 18, 2019, on 47 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical LQDA trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.43%
Narrow Range Bar Range Contraction -4.43%
NR7 Range Contraction -4.43%
NR7-2 Range Contraction -4.43%
Inside Day Range Contraction -4.43%
Wide Bands Range Expansion -4.43%
Oversold Stochastic Weakness -4.43%
NR7 Range Contraction -4.43%

Older signals for LQDA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Biopharmaceutical Health Life Sciences Pharmaceutical Pharmaceutical Industry Pain Medication Clinical Trial Pulmonary Arterial Hypertension Two River Treprostinil
Is LQDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 27.44
52 Week Low 3.25
Average Volume 40,064
200-Day Moving Average 8.5464
50-Day Moving Average 4.0954
20-Day Moving Average 4.218
10-Day Moving Average 3.747
Average True Range 0.4444
ADX 26.29
+DI 12.7973
-DI 23.012
Chandelier Exit (Long, 3 ATRs ) 3.9768
Chandelier Exit (Short, 3 ATRs ) 4.6932
Upper Bollinger Band 5.3137
Lower Bollinger Band 3.1223
Percent B (%b) 0.15
BandWidth 51.953532
MACD Line -0.224
MACD Signal Line -0.123
MACD Histogram -0.1011
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.99
Resistance 3 (R3) 4.04 3.90 3.90
Resistance 2 (R2) 3.90 3.77 3.88 3.87
Resistance 1 (R1) 3.68 3.68 3.61 3.63 3.84
Pivot Point 3.54 3.54 3.51 3.52 3.54
Support 1 (S1) 3.32 3.41 3.25 3.27 3.06
Support 2 (S2) 3.18 3.32 3.16 3.03
Support 3 (S3) 2.96 3.18 3.00
Support 4 (S4) 2.91